Tyrosinase-derived peptide–Major Histocompatibility Complex (MHC) on plasmacytoid dendritic cells (TYR-MHC-pDC)

The tyrosinase-derived peptide–Major Histocompatibility Complex (MHC) on plasmacytoid dendritic cells (pDCs) is a specialized immunological target primarily utilized in the development of therapeutic vaccines for melanoma (Tel et al., 2013, Cancer Research). Tyrosinase is a rate-limiting enzyme in melanin production that is highly expressed in melanoma cells, and its derived peptides (such as YMDGTMSQV) serve as potent tumor-associated antigens when presented by HLA molecules (UniProt P14679). Plasmacytoid dendritic cells are a distinct subset of immune cells that combine the ability to produce high levels of type I interferons with the capacity to present antigens and prime cytotoxic T lymphocytes (PubMed: 23824744). By targeting this complex, therapies aim to exploit the unique migratory and immunostimulatory properties of pDCs to initiate a robust, systemic anti-tumor immune response. Clinical trials have explored the use of autologous pDCs loaded ex vivo with tyrosinase peptides as a method to overcome tumor-induced immune suppression (NCT00928239). This target is unique because it involves the specific presentation context of the pDC, which can migrate to T-cell rich areas of lymph nodes more efficiently than other dendritic cell types. While promising, the primary safety concern involves on-target, off-tumor activity, where the immune system attacks healthy melanocytes, leading to vitiligo. Efficacy is typically monitored through the expansion of tyrosinase-specific T cells and changes in tumor burden. The complex serves as a bridge between innate and adaptive immunity, leveraging the pDC cytokine profile to enhance T-cell effector function. Overall, this target represents a precision medicine approach to immunotherapy, requiring specific HLA matching and antigen expression verification.

Other names

Tyrosinase peptide-HLA complexpDC-presented tyrosinase antigenTyrosinase-MHC class I complexHLA-A2-tyrosinase complexTyrosinase-derived peptide-HLA-A*02:01 complex

Induction of antigen-specific CD8+ T-cell responses through the presentation of tumor-associated antigens by plasmacytoid dendritic cells to the T-cell receptor, leading to the targeted destruction of tyrosinase-expressing tumor cells.